IP Library Granted Patent US 11,555,816
Granted Patent B2
US 11,555,816 · App. 16/436,700 · Granted Jan 17, 2023

Detection of amniotic fluid in vaginal secretions of pregnant women due to premature rupture of fetal membranes

Inventors: Glen Ford (Montgomery Village, MD); William Dean Wallace (Lehi, UT)
Assignee: Clinical Innovations, LLC
G01N33/558B01L3/5023G01N2333/471G01N2800/368
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,555,816
App. No.
16/436,700
Granted
Jan 17, 2023
Kind
B2
Abstract

A method is taught for the accurate determination of the premature rupture of membranes (PROM), defined as spontaneous rupture of membranes before the onset of uterine contractions. More specifically, a lateral flow assay strip tests for at least two antigens to greatly limit or eliminate the possibility of false negatives. A built-in timer in the cassette holding the lateral flow assay further increases the accuracy of the test. A collection buffer vial with self-contained shipping and dropper caps and built-in stand is also taught.

Claims (25)

1. A method for detecting biomarkers in a fluid sample taken from the vaginal secretions of a pregnant woman, the method comprising:

a) adding a buffered solution sample comprising the fluid sample taken from the vaginal secretions of the pregnant woman and a buffer, to a sample receiving pad of a chromatographic specific binding assay strip device comprising

i) a non-permeable platform strip;

ii) a permeable membrane testing strip positioned on top of the non-permeable platform strip, the permeable membrane testing strip comprising a test site for detecting the premature rupture of fetal membranes, the test site comprising a blend, wherein the blend comprises at least:

1) a first set of polyclonal antibodies for detecting α-fetoprotein;

2) a second set of polyclonal antibodies for detecting placental protein 12;

3) a first set of monoclonal antibodies specific for detecting α-fetoprotein; and

4) a second set of monoclonal antibodies specific for detecting placental protein 12;

wherein the ratio of polyclonal antibodies blended together are from 75% placental protein 12 to 25% α-fetoprotein antibodies;

iii) a sample receiving pad positioned on top of and at a proximal end of the non-permeable platform strip while in contact with a proximal end of the permeable membrane testing strip;

iv) a reservoir pad positioned on top of and at a distal end of the non-permeable platform strip while in contact with a distal end of the permeable membrane testing strip; and

v) a conjugate pad positioned on top of or below the sample receiving pad, the conjugate pad comprising a permeable membrane containing a conjugate, the conjugate comprising a colorant attached to antibodies that bind with analytes in the sample, wherein the conjugate of the sample binds to the analytes to form conjugate tagged analytes;

b) allowing time for conjugate tagged analytes to migrate along the length of the permeable membrane strip to the test site; and

c) detecting binding between α-fetoprotein, placental protein 12, and their respective monoclonal and polyclonal antibodies at the test site.

2. The method according to claim 1 , wherein the first set of monoclonal antibodies and the second set of monoclonal antibodies are fixed to the colorant on the conjugate pad.

3. The method according to claim 2 , wherein the first and second set of polyclonal antibodies are positioned at the test site in the shape of a “plus” sign.

4. The method according to claim 1 , wherein the first and second set of polyclonal antibodies are intermingled with the first and second set of monoclonal antibodies.

5. The method according to claim 4 , wherein the first and second set of polyclonal antibodies intermingled with the first and second set of monoclonal antibodies are positioned at the test site in the shape of a “plus” sign.

6. The method according to claim 1 , further comprising:

detecting an additional biomarker or biomarkers selected from the group consisting of β-prolactin, hCG, fetal fibronectin, and combinations thereof.

7. The method according to claim 6 , wherein α-fetoprotein biomarkers and prolactin biomarkers are tested in combination with placental protein 12 biomarker to detect a fetal membrane rupture.

8. The method according to claim 1 , wherein the chromatographic specific binding assay strip device further comprises:

a semi-permeable membrane, said semi-permeable membrane being positioned between the sample receiving pad and the conjugate pad and the conjugate pad residing on top of the semi-permeable membrane.

9. The method according to claim 1 , wherein the chromatographic specific binding assay strip device further comprises:

a semi-permeable membrane positioned over the conjugate pad, the conjugate pad being positioned over the sample receiving pad.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 2, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: CLINICAL INNOVATIONS, LLC
Reel/Frame 066984/0380 →
SECURITY INTEREST Recorded Apr 2, 2024
From: CLINICAL INNOVATIONS, LLC; COGENTIX MEDICAL, INC.; UROPLASTY, LLC; GI SUPPLY, INC.; LABORIE MEDICAL TECHNOLOGIES CANADA ULC; LABORIE MEDICAL TECHNOLOGIES CORP.; MEDICAL MEASUREMENT SYSTEMS B.V.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066986/0500 →
SECURITY INTEREST Recorded Mar 30, 2020
From: CLINICAL INNOVATIONS, LLC
To: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 052259/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2019
From: WALLACE, WILLIAM DEAN; FORD, GLEN
To: CLINICAL INNOVATIONS, LLC
Reel/Frame 051159/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2019
From: WALLACE, WILLIAM DEAN; FORD, GLEN
To: CLINICAL INNOVATIONS, LLC
Reel/Frame 051486/0301 →